Nanjing Han Xin Pharmaceutical Technology

Nanjing Han Xin Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on high-prevalence metabolic diseases, such as hyperuricemia and gout, as well as oncology and cardiovascular conditions. Its lead candidate, HX301, is a potent URAT1 inhibitor designed to treat chronic gout by promoting uric acid excretion and has shown promising results in clinical trials. Han Xin leverages its internal R&D capabilities to advance a pipeline of candidates from early discovery through clinical validation. The company aims to provide high-quality, affordable innovative medicines to patients globally, with a strong initial focus on the Chinese market.